PERCEPTIVE ADVISORS LLC - 21 Dec 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
10%+ Owner
Signature
/s/ Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager By: Joseph Edelman, its managing member
Issuer symbol
VRCA
Transactions as of
21 Dec 2023
Net transactions value
+$3,256,191
Form type
4
Filing time
26 Dec 2023, 19:21:16 UTC
Previous filing
19 Dec 2023
Next filing
29 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $1,234,000 +200,000 +3.2% $6.17 6,472,914 21 Dec 2023 See Footnote F1, F4
transaction VRCA Common Stock Purchase $1,667,500 +250,000 +3.9% $6.67 6,722,914 22 Dec 2023 See Footnote F2, F4
transaction VRCA Common Stock Purchase $354,691 +54,652 +0.81% $6.49 6,777,566 26 Dec 2023 See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.00 to $6.52 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.
F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.26 to $6.89 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.
F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.395 to $6.50 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.
F4 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.